New Guidelines Streamline Pulmonary Embolism Evaluation and Management

Recent guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) offer a comprehensive, evidence-based approach to evaluating and managing acute pulmonary embolism (PE) in adults.¹ Developed in collaboration with eight additional societies, the guidelines emphasize a multidisciplinary approach to care, recognizing the involvement of emergency departments, inpatient settings, and outpatient clinics.

Acute PE Clinical Categories

A central component of the new guidelines is the introduction of five “Acute PE Clinical Categories” (A-E) with subcategories. This framework aims to define the severity of PE, improve prognostic accuracy, and guide therapeutic decisions.¹

• Category A (Subclinical): Individuals in this category can often be safely discharged home from the emergency room without hospitalization.
• Category B (Symptomatic/Low Clinical Severity): Early discharge is generally appropriate for patients in this category.
• Categories C-E (Elevated Clinical Severity): Hospitalization is recommended for symptomatic patients with higher clinical severity scores to optimize treatment strategies. These strategies may include anticoagulation therapy or advanced therapies such as systemic thrombolysis, catheter-based thrombolysis, mechanical thrombectomy, or surgical embolectomy.

Anticoagulation Guidance

The guidelines recommend low-molecular-weight heparin over unfractionated heparin for initial parenteral anticoagulant therapy in patients with acute PE.¹ For patients eligible for oral anticoagulation, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists to minimize major bleeding and prevent recurrent venous thromboembolism, unless contraindicated.¹ Continued anticoagulation beyond the initial three- to six-month treatment phase is recommended for patients experiencing their first acute PE without a major reversible risk factor and/or those with a persistent risk factor.²

Risk Factors for Pulmonary Embolism

Assessment for PE risk factors during a targeted history and physical examination should include recent surgery, hospitalization, immobility, pregnancy, estrogen use, trauma, cancer, inflammatory disorders, and inherited or acquired thrombophilias.¹ Additional risk factors, which may vary by sex, include atherosclerotic cardiovascular disease, pulmonary disease, cancer, chronic venous disease, prolonged immobility, and hormonal therapy.¹

The Role of Pulmonary Embolism Response Teams (PERTs)

The guidelines highlight the importance of PERTs in improving the timeliness of care.¹ These teams can include representatives from vascular medicine, pharmacy, nursing, emergency medicine, cardiac surgery, and the patient/family, fostering diverse insights for risk stratification, selection of advanced therapies, and improved follow-up care and clinician education.¹

Areas for Future Research

The authors acknowledge existing evidence gaps, particularly in refining risk stratification tools. Validating the ACC/AHA clinical categories and integrating novel predictors like thrombus burden and right ventricular enlargement metrics are identified as key areas for future research.¹

Key Takeaways

• New guidelines provide a structured approach to PE evaluation and management using five clinical categories.
• DOACs are preferred over vitamin K antagonists for oral anticoagulation when appropriate.
• Continued anticoagulation is recommended for many patients after the initial treatment phase.
• PERTs can significantly improve the quality and timeliness of PE care.

“There have been significant advances in the understanding of pulmonary embolism and treatments to effectively manage this condition,” said Writing Committee Chair Mark A. Creager, MD, FACC. “This guideline is a road map to aid clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”¹

Sources:

1. Interventional Therapies for Acute Pulmonary Embolism – AHA Journals.
2. Pulmonary Embolism Guideline Comparison: Key Points – ACC.org.